» Articles » PMID: 17189621

Chronic Cocaine Exposure in the SCID Mouse Model of HIV Encephalitis

Overview
Journal Brain Res
Specialty Neurology
Date 2006 Dec 27
PMID 17189621
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical and preclinical evidence suggests that cocaine exposure hastens progression of the HIV disease process. An established active, euphoric dose of cocaine (20 mg/kg) was administered to SCID mice according to a regimen consistent with exposure to the drug by cocaine-abusing HIV-infected patients to determine the effects of cocaine on four previously established pathological characteristics of HIV encephalitis: cognitive deficits, fatigue, astrogliosis, and microgliosis. Mice were intracranially inoculated with either HIV-infected, or uninfected macrophages and then injected with either cocaine or saline in a 2 (Infection)x2 (Cocaine) factorial design. Cognition was assessed by acquisition and retention of a spatially cued learning task. Fatigue was assessed by monitoring motor activity following a 2 min forced swim. Mice were then sacrificed to determine the extent of astrogliosis and microgliosis in the four groups. Results indicated that in comparison to uninfected controls, HIV positive mice had increased astrogliosis and microgliosis, cognitive deficits, and recovered more slowly from fatigue. However, despite evidence that the cocaine exposure regimen activated the central nervous system and had long-term CNS effects, the drug did not alter the behavioral or the neuropathological deficits noted in HIV-infected SCID mice.

Citing Articles

HIV-1 and drug abuse comorbidity: Lessons learned from the animal models of NeuroHIV.

Sil S, Thangaraj A, Chivero E, Niu F, Kannan M, Liao K Neurosci Lett. 2021; 754:135863.

PMID: 33794296 PMC: 8108725. DOI: 10.1016/j.neulet.2021.135863.


HIV Neuropathogenesis in the Presence of a Disrupted Dopamine System.

Nickoloff-Bybel E, Calderon T, Gaskill P, Berman J J Neuroimmune Pharmacol. 2020; 15(4):729-742.

PMID: 32506353 PMC: 7905900. DOI: 10.1007/s11481-020-09927-6.


New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System.

Rojas-Celis V, Valiente-Echeverria F, Soto-Rifo R, Toro-Ascuy D Cells. 2019; 8(10).

PMID: 31614895 PMC: 6829584. DOI: 10.3390/cells8101245.


Heavy Alcohol Use and Age Effects on HIV-Associated Neurocognitive Function.

Cohen R, Gullett J, Porges E, Woods A, Lamb D, Bryant V Alcohol Clin Exp Res. 2018; 43(1):147-157.

PMID: 30371953 PMC: 6467512. DOI: 10.1111/acer.13915.


Cocaine potentiates cathepsin B secretion and neuronal apoptosis from HIV-infected macrophages.

Zenon F, Segarra A, Gonzalez M, Melendez L J Neuroimmune Pharmacol. 2014; 9(5):703-15.

PMID: 25209871 PMC: 4209444. DOI: 10.1007/s11481-014-9563-z.


References
1.
Kuzmin A, Johansson B, Fredholm B, Ogren S . Genetic evidence that cocaine and caffeine stimulate locomotion in mice via different mechanisms. Life Sci. 2000; 66(8):PL113-8. DOI: 10.1016/s0024-3205(99)00647-5. View

2.
Avgeropoulos N, Burris G, Ohlandt G, Wesselingh S, Markham R, Tyor W . Potential relationships between the presence of HIV, macrophages, and astrogliosis in SCID mice with HIV encephalitis. J NeuroAIDS. 2006; 2(1):1-20. DOI: 10.1300/J128v02n01_01. View

3.
Myrick H, Henderson S, Brady K, Malcolm R . Gabapentin in the treatment of cocaine dependence: a case series. J Clin Psychiatry. 2001; 62(1):19-23. DOI: 10.4088/jcp.v62n0105. View

4.
Myrick H, Henderson S, Brady K, Malcom R, Measom M . Divalproex loading in the treatment of cocaine dependence. J Psychoactive Drugs. 2001; 33(3):283-7. DOI: 10.1080/02791072.2001.10400575. View

5.
Dackis C, OBrien C . Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat. 2001; 21(3):111-7. DOI: 10.1016/s0740-5472(01)00192-1. View